Acceptability and characteristics of 124 human bioequivalence studies with active substances classified according to the Biopharmaceutic Classification System

British Journal of Clinical Pharmacology

Volumn 70, Issue 5, 2010, Pages 694-702

  Ramirez, Elena ^a   Laosa, Olga ^a   Guerra, Pedro ^a   Duque, Blanca ^a   Mosquera, Beatriz ^a   Borobia, Alberto M ^a   Lei, Suhua H ^a   Carcas, Antonio J ^a   Frias, Jesus ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Bioequivalence studies; Biopharmaceutics classification system

Indexed keywords

ACECLOFENAC; AMLODIPINE; AZITHROMYCIN; BROMAZEPAM; CLARITHROMYCIN; CLAVULANIC ACID; CLOPIDOGREL; CODEINE; DEFLAZACORT; FLUTAMIDE; IBUPROFEN; IRBESARTAN; ISONIAZID; LERCANIDIPINE; LISINOPRIL; LORATADINE; LORMETAZEPAM; LOSARTAN; MEVINOLIN; ONDANSETRON; PENTOXIFYLLINE; PRAVASTATIN; PYRAZINAMIDE; RANITIDINE; RIFAMPICIN; RISPERIDONE; SILDENAFIL; SIMVASTATIN; UNINDEXED DRUG; ZOLPIDEM;

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; DRUG CLASSIFICATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG SOLUBILITY; HUMAN; MAJOR CLINICAL STUDY; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; AREA UNDER CURVE; CROSS-OVER STUDIES; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; THERAPEUTIC EQUIVALENCY;

EID: 78649247553     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2010.03757.x     Document Type: Article

References (20)

1. FDA. 21CFR320.1 PART 320 - Bioavailability and Bioequivalence requirements. 2000. Revised as of April 1, 2003.
2. Directive 2004/27/EC of the European Parliament and the Council of 31 March 2004 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use Official Journal L - 136, 30/04/2004. 34-57.
3. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products- General Considerations, Office of Training and Communications, Division of Communications Management, Drug Information Branch, HFD-210. Rockville MD 20857, March 2003.
4. EMEA/CPMP/EWP/1401/98. Note for guidance on the investigation of bioavailability and bioequivalence. EMEA, London, 26 July 2001.
5. Pan American Health Organization. Regional Office of the World Health Organization. Science based criteria for bioequivalence in vivo and in vitro, bio-waivers, and strategic framework for implementation. Draft. Available at: http://www.paho.org/english/ad/ths/ev/be-doct-draft-eng.pdf (last accessed 7 March 2010).
6. Amidon GL, Lennernäs H, Shah VP, Crison JR. A theorical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995; 12: 413-20.
7. U.S. Food and Drug Administration, Guidance for Industry. Food and Drug Administration, Rockville MD. 2000.Waiver of in vivo bioavailability and bioequivalence studies for immediate release solid oral dosage forms based on a biopharmaceutics classification system. Available at: http://www.fda.gov/RegulatoryInformation/Guidances/default.htm (last accessed 7 March 2010).
8. EMEA/CPMP/EWP/QWP/1401/98 Rev.1/Corr*. Guideline on the investigation of bioequivalence. London, 20 January 2010. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/W500070039.pdf (last accessed 7 March 2010).
9. Yu LX, Amidon GL, Polli GL, Zhao H, Mehta MU, Conner DL, Shah VP, Lesko LJ, Chen ML, Lee VHL, Hussain AS. Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm Res 2002; 19: 921-5.
10. Blume HH, Schug BS. The biopharmaceutics classification system (BCS): class III drugs-better candidate for BA/BE waiver? Eur J Pharm Sci 1999; 9: 117-21.
11. Polli JE, Yu LX, Cook JA, Amidon GL, Borchardt RT, Burnside BA, Burton PS, Chen ML, Conner DP, Faustino PJ, Hawi AA, Hussain AS, Joshi HN, Kwei G, Lee VHL, Lesko LJ, Lipper RA, Loper AE, Nerurkar SG, Polli JW, Sanvordeker DR, Taneja R, Uppoor RS, Vattikonda CS, Wilding I, Zhang G. Summary workshop report: biopharmaceutics classification system-implementation challenges and extension opportunities. J Pharm Sci 2004; 93: 1375-81.
12. Cheng CL, Yu LX, Lee HL, Yang CY, Lue CS, Chou CH. Biowaiver extension potential to BCS Class III high solubility-low permeability drugs: bridging evidence for metformin immediate-release tablet. Eur J Pharm Sci 2004; 22: 297-304.
13. Proposal to waive in vivo bioequivalence requirements for WHO Model List of Essential Medicines immediate-release, solid oral dosage forms. Technical Report Series, No 937, 40th Report, Annex 8 of WHO Expert committee on specifications for pharmaceutical preparations. Available at: http://whqlibdoc.who.int/trs/WHO_TRS_937_eng.pdf (last accessed 7 March 2010).
14. Ramirez E, Guerra P, Laosa O, Duque B, Tabares B, Lei AS, Carcas AJ, Frias J. The importance of sample size, log-mean ratios, and intra-subject variability in the acceptance criteria of bioequivalence studies. Eur J Clin Pharmacol 2008; 64: 783-93.
15. Biopharmaeutics Classification System (BCS). Therapeutic System Research Laboratories (TSRL inc.). Available at: http://www.tsrlinc.com/services/bcs/search.cfm.
16. Takagi T, Ramadrasekharan C, Bermejo M, Yamashita S, Yu LX, Amidon LG. A provisional Biopharmaceutical Classification of the Top 200 oral drugs products in the Unites States, Great Britain, Spain and Japan. Mol Pharm 2006; 3: 631-43.
17. Hauschke D, Steinijans VW, Diletti E, Burke M. Sample size determination for bioequivalence assessment using a multiplicative model. J Pharmacokinet Biopharm 1992; 20: 557-61.
18. Julious SA. Tutorial in biostatistics. Statistic Med 2004; 23: 1921-86.
19. Wu CY, Benet LZ. Predicting drug disposition via application of BCS: Transport /absorption /elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 2005; 22: 11-23.
20. Orange Book Preface, Statistical Criteria for Bioequivalence. Approved Drug Products with Therapeutic Equivalente Evaluations. 29th Edition. U.S. Food and Drug Administration. Center for Drug Evaluation and Research. 2009-06-18. 2009. Available at: http://www.fda.gov/drugs/developmentapprovalprocess/ucm079068.htm.